Higher Hepatitis C Cure Rates in a Patient-Centered Medical Home Compared to Specialist Care

• Published in: Journal of primary care & community health 2023-01, Vol.14, p.21501319231219576-21501319231219576
• Main Authors: Hughes, Jonathan, Hodge, Nicholas, Shadoan, Amber, Ellis, Courtney, Turner, Ben, Glass, Craig
• Format: Article
• Language: English
• Subjects: Adult; Antiviral Agents - therapeutic use; Antiviral drugs; Candidates; Clinical outcomes; Clinical Research and Quality Improvement in Family Medicine Clinics; Cure; Hepacivirus; Hepatitis C; Hepatitis C - drug therapy; Hepatitis C, Chronic - drug therapy; Humans; Interdisciplinary aspects; Medical education; Medical personnel; Patient-Centered Care; Patients; Primary care; Quasi-experimental methods; Risk factors; Specialists; Treatment Outcome
• ISSN: 2150-1319; 2150-1327
• DOI: 10.1177/21501319231219576

Purpose: The new era of direct-acting antivirals (DAAs) against the hepatitis C virus (HCV) has led many primary care clinicians to begin treating HCV. Nevertheless, many patients are referred to specialists due to comorbidities, care complexities, and knowledge gaps of the primary care provider. We compared clinical outcomes for patients treated within a Family Medicine Residency Program (FMRP) affiliated patient-centered medical home (PCMH) with those referred to a specialist. Methods: Following didactic education and development of practice resources we conducted a single-center quasi-experimental study of adults with HCV referred for treatment either internally or externally to a specialist between January 2019 and December 2020. The primary outcome was the number of patients with a sustained virologic response at 12 weeks after treatment (SVR12), utilizing an intention-to-treat analysis. Results: During the study period 107 patients were assessed by the PCMH, of whom 24 were deemed not a good candidate for treatment. Of the 83 patients referred for treatment, 36 patients were referred externally and 47 were treated internally. While the rate of SVR12 was 100% for both groups when analyzed per protocol (ie, only patients who completed treatment and attended all follow-ups), the rate of SVR12 was 31% for patients referred externally and 62% for patients treated internally when analyzed by intention to treat (relative risk [RR] 2.02, 95% CI 1.18-3.47, P = .01). This difference was entirely attributable to differences in lost to follow-up rates. Conclusions: Following education and creation of practice resources, achievement of SVR12 among patients with HCV treated by an internal interdisciplinary family medicine team was superior to those who were externally referred. This was primarily attributable to differences in follow-up rates.